Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin

por Gonzalez, M A, Biswas, S, Clifton, L, Corrie, P G
Publicado 2003

Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009–2010)

por Liniker, E, Harrison, M, Weaver, J M J, Agrawal, N, Chhabra, A, Kingshott, V, Bailey, S, Eisen, T G G, Corrie, P G
Publicado 2013

Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients

por Corrie, P G, Shaw, J, Spanswick, V J, Sehmbi, R, Jonson, A, Mayer, A, Bulusu, R, Hartley, J A, Cree, I A
Publicado 2005

SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare Professionals Working with Cancer Patients during the First Wave of the COVID-19 Pandemic

por Favara, D.M., McAdam, K., Cooke, A., Bordessa-Kelly, A., Budriunaite, I., Bossingham, S., Houghton, S., Doffinger, R., Ainsworth, N., Corrie, P.G.
Publicado 2021

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

por Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Publicado 2018

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

por Kefford, R F, Thomas, N P B, Corrie, P G, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, M, Mortimer, P, Watson, A J, Margison, G P, Middleton, M R
Publicado 2009

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications

por Corrie, P G, Bulusu, R, Wilson, C B, Armstrong, G, Bond, S, Hardy, R, Lao-Sirieix, S, Parashar, D, Ahmad, A, Daniel, F, Hill, M, Wilson, G, Blesing, C, Moody, A M, McAdam, K, Osborne, M
Publicado 2012

Is community treatment best? a randomised trial comparing delivery of cancer treatment in the hospital, home and GP surgery

por Corrie, P G, Moody, A M, Armstrong, G, Nolasco, S, Lao-Sirieix, S-H, Bavister, L, Prevost, A T, Parker, R, Sabes-Figuera, R, McCrone, P, Balsdon, H, McKinnon, K, Hounsell, A, O'Sullivan, B, Barclay, S
Publicado 2013

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

por Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.
Publicado 2020

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

por Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A, Middleton, M R
Publicado 2018

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

por Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A, Middleton, M R
Publicado 2019